Truist analyst Gregory Renza lowered the firm’s price target on Fulcrum Therapeutics (FULC) to $17 from $18 and keeps a Buy rating on the shares. The firm caught up with management after the company reported Q4 results in tandem with Full Cohort 4 data for pociredir. The data met management’s targeted ranges, the analyst tells investors in a research note, and the firm is now looking ahead to Q2 updates following Fulcrum’s meeting with the FDA for details on the develompental/regulatory path forward, and approach to maximizing pociredir’s strategic value.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum PIONEER data reinforce pociredir differentiated profile, Wainwright says
- Fulcrum Therapeutics move lower ‘overdone,’ says Stifel
- Truist remain buyers of Fulcrum Therapeutics shares on weakness
- Fulcrum Therapeutics announces results from Phase 1b PIONEER trial of pociredir
- Fulcrum Therapeutics reports Q4 EPS (31c), consensus (30c)